Ignite Creation Date:
2024-05-06 @ 4:11 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04890041
Status:
UNKNOWN
Last Update Posted:
2022-10-31
First Post:
2021-05-12
Brief Title:
TPO-RA in Primary Immune Thrombocytopenia ITP in Patients Older Than 14 Years
Sponsor:
Institute of Hematology Blood Diseases Hospital China
Organization:
Institute of Hematology Blood Diseases Hospital China
Study Overview
Official Title:
Efficacy of TPO-RA in the Management of Primary Immune Thrombocytopenia ITP in Patients Older Than 14 Years With Poor First-line Response a Multi-center Prospective One-arm Study
Status:
UNKNOWN
Status Verified Date:
2022-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ITP
Brief Summary:
This multi-center study aims to study the efficacy of TPO-RAs transformation in Chinese ITP patients older than 14 years This study will be conducted in ITP patients who had not responded to first-line in the previous treatment
Detailed Description:
The primary objective of this study was to evaluate the efficacy of TPO-RAs transformation in Chinese ITP patients older than 14 years who had not responded to first-line in the previous treatment
100 eligible subjects will be enroll ed in this studyThe dose will be adjusted according to the subject platelet count during the period from week 1 to week 6
100 eligible subjects will be enroll ed in this studyThe dose will be adjusted according to the subject platelet count during the period from week 1 to week 6
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None